Physician profile
William D Thomas
NPI 1386811073
$8,732.55
in general payments reported to CMS, 2019-2025
45 companies · $53.45 in 2025
The $53.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,580 · 2020: $1,671 · 2021: $2,923 · 2022: $2,010 · 2023: $141 · 2024: $353 · 2025: $53.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $548.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $933.38 | 2019-2022 | |
| Lilly USA, LLC | $927.91 | 2019-2023 | Mounjaro |
| Abbvie INC. | $819.62 | 2020-2023 | Qulipta |
| Astrazeneca Pharmaceuticals LP | $773.61 | 2019-2024 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $642.58 | 2019-2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.69 | 2019-2022 | |
| Pfizer INC. | $319.27 | 2019-2022 | |
| Amgen INC. | $280.20 | 2019-2025 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $276.81 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $276.21 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $243.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $242.26 | 2019-2022 | |
| Astellas Pharma US INC | $238.29 | 2019-2021 | |
| Allergan, INC. | $200.35 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.